Hsieh K H, Chang J S, Wu H L, Chu C T
Asian Pac J Allergy Immunol. 1987 Jun;5(1):13-6.
Recombinant interleukin-2 (RIL-2) and lymphokine-activated killer (LAK) cells were administered to 2 boys with the end-stage of primary hepatocellular carcinoma (HCC); the efficacy and toxicity were evaluated. Immunologically, the natural killer and LAK activities were enhanced. Clinically, the side effects were similar to those reported for adults but milder. This kind of treatment may be considered for children with the early stages of hepatocellular carcinoma.
将重组白细胞介素-2（RIL-2）和淋巴因子激活的杀伤细胞（LAK）用于2例原发性肝细胞癌（HCC）终末期男孩，评估其疗效和毒性。免疫方面，自然杀伤活性和LAK活性增强。临床方面，副作用与成人报道的相似，但较轻。对于早期肝细胞癌患儿可考虑这种治疗方法。
